<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01944787</url>
  </required_header>
  <id_info>
    <org_study_id>12-05-SP-50</org_study_id>
    <nct_id>NCT01944787</nct_id>
  </id_info>
  <brief_title>Hydration and Rate of Cesarean Delivery Among Nulliparous</brief_title>
  <official_title>Intrapartum Hydration and Rate of Cesarean Delivery Among Nulliparous at &gt; 37 Weeks: A Multicenter Randomized</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chauhan, Suneet P., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chauhan, Suneet P., M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the present study is the hydration of nulliparous women with 250ml/hour vs.&#xD;
      125ml/hrs would decrease the rate of primary cesarean section.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this non-blinded randomized clinical trial (RCT) we will recruit approximately 670 women&#xD;
      which meet the inclusion criteria across three sites (Eastern Virginia Medical School (EVMS),&#xD;
      University of Arkansas for Medical Sciences (UAMS) and Obstetrix Medical Group, in&#xD;
      California). When the patient is being scheduled for induction by her physician or when she&#xD;
      presents to L&amp;D for induction or in labor, but her cervical dilation on admission is less&#xD;
      than 4 cm, the participants will be consented, and then randomized into a study intervention&#xD;
      group. Both groups will receive maintenance IV hydration with Lactated Ringer's (LR)&#xD;
      solution: Group I will receive LR at 125 ml/hr and group II will receive LR at 250ml/hr.&#xD;
      Other than the rate of maintenance IV infusion, the two groups will receive routine&#xD;
      intrapartum care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of cesarean section</measure>
    <time_frame>5 Years</time_frame>
    <description>The primary objective of this multi-center RCT is to determine if hydration with 250 ml/hr, when compared to traditional 125 ml/hr, significantly decreases the rate of primary cesarean delivery nulliparous.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>labor</measure>
    <time_frame>5 Years</time_frame>
    <description>The secondary objectives of this randomized trial are to compare the 2 groups regarding:&#xD;
Time from randomization to delivery (minutes)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The rate of tachysystole (uterine contractions more than 5 in 10 minutes, n/%)</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The rate of non-reassuring fetal-heart reassuring tracing treated with terbutaline or other tocolytic agent (n/%)</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The indication for cesarean delivery (n/%) versus The indication for operative vaginal delivery (n/%)</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Maternal complications (as diagnosed by managing clinician, (n/%) for all):</measure>
    <time_frame>5 years</time_frame>
    <description>chorioamnionitis&#xD;
endometritis&#xD;
wound infection&#xD;
wound disruption&#xD;
blood transfusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Neonatal outcomes (as diagnosed by managing clinician, (n/%) for all):</measure>
    <time_frame>5 Years</time_frame>
    <description>Apgar score at 1 and 5 min&#xD;
Birth weight (grams)&#xD;
Gender (male/female/unknown)&#xD;
Umbilical arterial pH if available (pH units)&#xD;
Umbilical arterial base excess if available (mmol/L)&#xD;
Admission to neonatal intensive care unit (n/%)&#xD;
Indication for NICU admission (n/%)&#xD;
Duration of hospitalization (days)&#xD;
Morbidity defined as one or more of the following as diagnosed by managing physician: Respiratory Distress Syndrome (RDS), Intraventricular Hemorrhage (IVH) grade III/ IV, Necrotizing Enterocolitis (NEC), proven sepsis,seizures (n/%)&#xD;
Mortality (n/%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Time of Randomization to complete dilation/ minutes</measure>
    <time_frame>5 Years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time from complete cervical dilation to delivery of newborn/ minutes</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time from delivery of newborn to delivery of placenta/ minutes</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">670</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Routine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Hydration at 125 cc hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Hydration at 250 cc hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine</intervention_name>
    <description>IV Hydration at 125 cc hour</description>
    <arm_group_label>Routine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV Hydration at 250cc hour</intervention_name>
    <description>IV Hydration at 250 cc hour</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• Non-anomalous singleton&#xD;
&#xD;
          -  Nulliparous (no prior delivery after 20 weeks)&#xD;
&#xD;
          -  Presenting at ≥37 weeks of gestation&#xD;
&#xD;
          -  Presenting for anticipated induction of labor or spontaneous labor (regular&#xD;
             contractions for more than 2 hours), but cervical dilation less than 4 cm&#xD;
&#xD;
          -  Rupture of membranes&#xD;
&#xD;
          -  Expected to deliver at one of the participating hospitals&#xD;
&#xD;
        Exclusion Criteria:• Not in the inclusion criteria&#xD;
&#xD;
          -  Autoimmune disorders (antiphospholipid antibody, lupus, rheumatoid arthritis,&#xD;
             scleroderma)&#xD;
&#xD;
          -  Diabetes mellitus-gestational or pre-gestational&#xD;
&#xD;
          -  Enrollment in another randomized clinical trial&#xD;
&#xD;
          -  Hematologic disorders (coagulation defects, sickle cell disease, thrombocytopenia,&#xD;
             thrombophilia)&#xD;
&#xD;
          -  Hypertension (chronic or pregnancy induced) before randomization&#xD;
&#xD;
          -  HIV (human immunodeficiency virus)&#xD;
&#xD;
          -  Placenta previa / 3rd trimester bleeding&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt; 1.5 mg/dL)&#xD;
&#xD;
          -  Restrictive lung disease&#xD;
&#xD;
          -  Seizure disorder on medication&#xD;
&#xD;
          -  Thyroid disease on medication&#xD;
&#xD;
          -  Any contraindications to vaginal delivery (breech, active herpes, schedule cesarean,&#xD;
             abnormal fetal heart tracing)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneet P Chauhan, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Andrew Combs, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrix Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suneet Chauhan, MD</last_name>
    <phone>757-672-5955</phone>
    <email>mfmchauhan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>C A Combs MD PhD</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>C A Combs, MD PhD</last_name>
      <phone>408-371-7111</phone>
      <phone_ext>130</phone_ext>
      <email>andrew_combs@obstsetrix.com</email>
    </contact>
    <contact_backup>
      <last_name>kimberly m mallory, RNC</last_name>
      <phone>4087613565</phone>
      <email>kimberly_mallory@pediatrix.com</email>
    </contact_backup>
    <investigator>
      <last_name>C A Combs, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 6, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2013</study_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

